These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21622725)

  • 21. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
    Kudo M
    Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
    Sennino B; Ishiguro-Oonuma T; Wei Y; Naylor RM; Williamson CW; Bhagwandin V; Tabruyn SP; You WK; Chapman HA; Christensen JG; Aftab DT; McDonald DM
    Cancer Discov; 2012 Mar; 2(3):270-87. PubMed ID: 22585997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
    Boere IA; Hamberg P; Sleijfer S
    Cancer Sci; 2010 Jan; 101(1):7-15. PubMed ID: 19860846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
    Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
    J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium].
    Kernt M; Thiele S; Hirneiss C; Neubauer AS; Lackerbauer CA; Wolf A; Eibl KH; Haritoglou C; Ulbig MW; Kampik A
    Ophthalmologe; 2011 May; 108(5):445-51. PubMed ID: 21253747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
    Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
    J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
    Jonker DJ; Rosen LS; Sawyer MB; de Braud F; Wilding G; Sweeney CJ; Jayson GC; McArthur GA; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate DM; Kollia G; Nuyten DSA; Galbraith S
    Ann Oncol; 2011 Jun; 22(6):1413-1419. PubMed ID: 21131369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
    Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
    Zhu H; Zhang C; Yang X; Yi C
    Medicine (Baltimore); 2019 Mar; 98(10):e14823. PubMed ID: 30855507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway.
    Wan Y; Wu W; Wan Y; Li L; Zhang J; Chen X; Liu S; Yao X
    Pharmacol Res; 2021 Aug; 170():105721. PubMed ID: 34116207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.